8/2/2007 11:50:12 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that they have licensed their antibody phage display libraries to Cambridge Antibody Technology (CAT), a wholly-owned subsidiary of AstraZeneca, for the discovery of therapeutic antibodies. CAT will receive sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’s technology. The agreement allows CAT the ability to commercialize up to 20 royalty bearing therapeutic antibody products. Financial terms of the agreement are not disclosed.
comments powered by